Please select the option that best describes you:
What are your top takeaways from ATS 2023?
Answer from: at Community Practice
The potential role of biologics in COPD
The importance of mucus in bronchitic type
Potential addition of Ensifentrine to COPD therapeutic options
After over ten years with no drug of a new class approved for COPD, there’s at least some hope for progress.
Sign in or Register to read more
Answer from: at Community Practice
Three standouts to me (as an ILD and acute lung injury doc/researcher...I'm biased to these sorts of talks):Tuesday, Clinical and Translational Studies in Mechanical Ventilation: RAPiD session, included studies investigating patient-vent interactions, treatment for septic shock, bioinformatics, and ...